Last reviewed · How we verify

MGL-3196 — Competitive Intelligence Brief

MGL-3196 (MGL-3196) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone receptor beta (THR-β) selective agonist. Area: Cardiovascular.

phase 3 Thyroid hormone receptor beta (THR-β) selective agonist THR-β (thyroid hormone receptor beta) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

MGL-3196 (MGL-3196) — Madrigal Pharmaceuticals, Inc.. MGL-3196 is a thyroid hormone receptor beta (THR-β) selective agonist that activates THR-β to reduce cholesterol and triglycerides while minimizing systemic thyroid hormone effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MGL-3196 TARGET MGL-3196 Madrigal Pharmaceuticals, Inc. phase 3 Thyroid hormone receptor beta (THR-β) selective agonist THR-β (thyroid hormone receptor beta)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone receptor beta (THR-β) selective agonist class)

  1. Madrigal Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MGL-3196 — Competitive Intelligence Brief. https://druglandscape.com/ci/mgl-3196. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: